Cargando…

Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients

INTRODUCTION: Combined antiretroviral therapy (cART) has improved survival in HIV-patients. While the first antiretrovirals, which became available in particular D-drugs (especially didanosine and stavudine) and unboosted protease inhibitors, may impair liver function, the modern cART seems to decre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anadol, Evrim, Lust, Kristina, Boesecke, Christoph, Schwarze-Zander, Carolynne, Mohr, Raphael, Wasmuth, Jan-Christian, Rockstroh, Jürgen Kurt, Trebicka, Jonel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773180/ https://www.ncbi.nlm.nih.gov/pubmed/29346443 http://dx.doi.org/10.1371/journal.pone.0191118

Ejemplares similares

Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?
por: Mohr, Raphael, et al.
Publicado: (2015)

Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
por: Bischoff, Jenny, et al.
Publicado: (2021)

Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART)
por: Dold, Leona, et al.
Publicado: (2017)

Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART
por: Dold, Leona, et al.
Publicado: (2019)

microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients
por: Austermann, Christian, et al.
Publicado: (2017)

Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis
por: Mohr, Raphael, et al.
Publicado: (2018)

Implementation of EACS vaccination recommendations among people living with HIV
por: Breitschwerdt, Sven, et al.
Publicado: (2022)

Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV
por: Dold, Leona, et al.
Publicado: (2023)

Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART)
por: Dold, Leona, et al.
Publicado: (2015)

Moderate endurance training (marathon-training) – effects on immunologic and metabolic parameters in HIV-infected patients: the 42 KM cologne project
por: Schlabe, Stefan, et al.
Publicado: (2017)

Transmission of Human Immunodeficiency Virus I Drug Resistance - a Case Report. What are the Clinical Implications?
por: Anadol, E, et al.
Publicado: (2010)

Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection
por: Jansen, Christian, et al.
Publicado: (2015)

Impact of COVID‐19 on HIV late diagnosis in a specialized German centre
por: van Bremen, Kathrin, et al.
Publicado: (2022)

Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005–2017
por: Stecher, Melanie, et al.
Publicado: (2020)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Correction to: Treatment modifcation after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005–2017
por: Stecher, Melanie, et al.
Publicado: (2021)

SARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study)
por: van Bremen, Kathrin, et al.
Publicado: (2021)

Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence
por: Vogel, M, et al.
Publicado: (2011)

HPV-associated anal lesions in HIV+ patients: long-term results regarding quality of life
por: Wesselmann, Paul, et al.
Publicado: (2020)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients
por: Dold, L., et al.
Publicado: (2020)

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Alterations of the NK cell pool in HIV/HCV co-infection
por: Kaczmarek, Dominik J., et al.
Publicado: (2017)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Rabies post-exposure prophylaxis in Germany − What are the challenges?
por: Meyerhoff, P., et al.
Publicado: (2021)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS
por: Jansen, Christian, et al.
Publicado: (2014)

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
por: Boesecke, Christoph, et al.
Publicado: (2017)

Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV
por: Spitsin, Sergei, et al.
Publicado: (2021)

PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension
por: Jansen, Christian, et al.
Publicado: (2014)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy
por: Krämer, Benjamin, et al.
Publicado: (2017)

Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV
por: Valcour, Victor G., et al.
Publicado: (2015)

Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis
por: Queck, Alexander, et al.
Publicado: (2020)

Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis
por: Praktiknjo, Michael, et al.
Publicado: (2020)

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?
por: Krastinova, Evguenia, et al.
Publicado: (2015)

Association between obesity and combination antiretroviral therapy (cART) adherence among persons with early-stage HIV infection initiating cART
por: Musinguzi, Nicholas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mfbqht2lsuk8kb6qd2gasvabq3